PTPN2

ArsenalBio Announces Presentations Highlighting Preclinical Data on AB-1015 and AB-2100 at ASGCT Annual Meeting

Retrieved on: 
Tuesday, May 16, 2023

The three posters will disclose features and findings on AB-2100, a novel integrated circuit T cell therapeutic candidate engineered for the treatment of kidney cancer.

Key Points: 
  • The three posters will disclose features and findings on AB-2100, a novel integrated circuit T cell therapeutic candidate engineered for the treatment of kidney cancer.
  • AB-2100 is ArsenalBio’s second pipeline program which is targeting the initiation of a phase 1 trial in 2024.
  • The following abstracts will be presented as an oral abstract session and three posters during the ASGCT annual meeting.
  • The SPA platform allows tuning of T cell biology to engineer T cell therapies with increased antitumor potency and cellular persistence.

ArsenalBio Announces Participation in Upcoming Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting

Retrieved on: 
Thursday, November 4, 2021

Full text of the abstract will be released on the SITC website on Tuesday, Nov. 9, 2021 at 8:00 a.m.

Key Points: 
  • Full text of the abstract will be released on the SITC website on Tuesday, Nov. 9, 2021 at 8:00 a.m.
  • ArsenalBio is a privately held, programmable cell therapy company focused on the realization of solid tumor cell therapy to defeat cancer.
  • Our team is engineering living medicines to attack cancers inherent multi-faceted nature and bring dramatic improvements to the lives of patients.
  • To learn more, visit www.arsenalbio.com and follow us on Twitter @ ArsenalBio , LinkedIn and Facebook .